Calcitonin oral transmucosal - Watson

Drug Profile

Calcitonin oral transmucosal - Watson

Alternative Names: Calcitonin buccal - Watson

Latest Information Update: 10 Apr 2008

Price : $50

At a glance

  • Originator Watson Laboratories
  • Class Neuropeptides; Peptide hormones
  • Mechanism of Action Calcitonin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 05 Feb 2003 No development reported - Preclinical for Postmenopausal osteoporosis in USA (Transmucosal)
  • 16 Jan 2001 TheraTech is now called Watson Laboratories
  • 23 Feb 1999 TheraTech is now a subsidiary of Watson Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top